Back to search results

Retatrutide for Obesity or Overweight Without Type 2 Diabetes

This study is testing a drug called Retatrutide (LY3437943) to see how well it helps people without type 2 diabetes lose weight and if it's safe. You might be able to join if you are 18 or older, have obesity (a Body Mass Index or BMI of 30 or higher) or are overweight (BMI of 27 or higher) with at least one weight-related health issue like high blood pressure, and have tried to lose weight with dieting before. The main goal is to see how much your body weight changes over 104 weeks. The current status of this study is unclear.

Study design
This interventional study plans to enroll 600 participants. It is testing different ways to increase the dose of Retatrutide.
What's involved
Participation in the study will last about 113 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your body weight will be measured at the beginning of the study and again at Week 104.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07357415

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
Eli Lilly and Company
~600 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Retatrutide

At a glance

Recruiting sites
0 of 35 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Body Weight
Measured over Baseline, Week 104

Conditions

Obesity
Overweight

Explore related trials

ObesityOverweight

Where it's being run

35 sites across 16 states
Canada10
Argentina5
Texas4
California2
Florida2
New York2
Arizona1
Hawaii1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a Body Mass Index (BMI) at screening
≥ 30 kilogram per square meter (kg/m2) OR
≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
Have at least one unsuccessful attempt to lose weight by dieting

Exclusion

Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
Have a prior or planned surgical treatment for obesity
Have type 1 diabetes or type 2 diabetes
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had within the past 90 days before screening:
heart attack
stroke
hospitalization for unstable angina or heart failure
Have New York Heart Association Functional Classification Class IV congestive heart failure
Have a history of chronic or acute pancreatitis
Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

What this trial measures

  • Percent Change from Baseline in Body WeightBaseline, Week 104